It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Macular Telangiectasia Type 2 (MacTel) is a rare degenerative retinal disease with complex genetic architecture. We performed a genome-wide association study on 1,067 MacTel patients and 3,799 controls, which identified eight novel genome-wide significant loci (p < 5 × 10−8), and confirmed all three previously reported loci. Using MAGMA, eQTL and transcriptome-wide association analysis, we prioritised 48 genes implicated in serine-glycine biosynthesis, metabolite transport, and retinal vasculature and thickness. Mendelian randomization indicated a likely causative role of serine (FDR = 3.9 × 10−47) and glycine depletion (FDR = 0.006) as well as alanine abundance (FDR = 0.009). Polygenic risk scoring achieved an accuracy of 0.74 and was associated in UKBiobank with retinal damage (p = 0.009). This represents the largest genetic study on MacTel to date and further highlights genetically-induced systemic and tissue-specific metabolic dysregulation in MacTel patients, which impinges on retinal health.
Melanie Bahlo and colleagues report a genome-wide association study on the retinal degenerative disease Macular Telangiectasia Type 2, identifying 8 new genome-wide significant loci. Further analyses suggest key roles for genes that transport and synthesize the amino acids serine, glycine and alanine, providing a more accurate genomic tool for identifying people at risk of the disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Walter and Eliza Hall Institute of Medical Research, Population Health and Immunity Division, Parkville, Australia (GRID:grid.1042.7); University of Melbourne, Department of Medical Biology, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
2 Moorfields Eye Hospital NHS Foundation Trust, London, UK (GRID:grid.436474.6) (ISNI:0000 0000 9168 0080); University College London Institute of Ophthalmology, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
3 The Lowy Medical Research Institute, La Jolla, USA (GRID:grid.489357.4)
4 The Lowy Medical Research Institute, La Jolla, USA (GRID:grid.489357.4); The Scripps Research Institute, Department of Molecular Medicine, La Jolla, USA (GRID:grid.214007.0) (ISNI:0000000122199231)
5 Moorfields Eye Hospital NHS Foundation Trust, London, UK (GRID:grid.436474.6) (ISNI:0000 0000 9168 0080)
6 Columbia University, Department of Ophthalmology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); Columbia University, Department of Pathology and Cell Biology, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)